07.30.21
Bristol Myers Squibb
2Q Revenues: $11.7 billion (+16%)
2Q Earnings: $1.1 billion (loss of $80 million 2Q20)
Comments: Revlimid sales were $3.2 billion in the quarter, up 11%. Eliquis sales were $2.8 billion, up 29%. Opdivo sales were $1.9 billion, up 16%. Orencia sales were $814 million, up 9%. Pomalyst /Imnovid sales were up 15% to $854 million. Sprycel sales were $541 million, up 6%. Yervoy sales were $510 million, up 38%. Abraxane sales were down 4% to $296 million, and Empliciti sales were down 11% to $86 million. Reblozyl sales reached $128 million in the quarter. Established Brands: Vidaza sales were down 64% to $45 million. Baraclude sales were down 10% to $109 million. Other brands revenue was $319 million, down 4% in the quarter. R&D expenses increased 30% to $3.3 billion in the quarter primarily due to higher license and asset acquisition charges and an in-process research and development (IPR&D) impairment charge.
Read Contract Pharma's Top Companies Report on BMS.
2Q Revenues: $11.7 billion (+16%)
2Q Earnings: $1.1 billion (loss of $80 million 2Q20)
Comments: Revlimid sales were $3.2 billion in the quarter, up 11%. Eliquis sales were $2.8 billion, up 29%. Opdivo sales were $1.9 billion, up 16%. Orencia sales were $814 million, up 9%. Pomalyst /Imnovid sales were up 15% to $854 million. Sprycel sales were $541 million, up 6%. Yervoy sales were $510 million, up 38%. Abraxane sales were down 4% to $296 million, and Empliciti sales were down 11% to $86 million. Reblozyl sales reached $128 million in the quarter. Established Brands: Vidaza sales were down 64% to $45 million. Baraclude sales were down 10% to $109 million. Other brands revenue was $319 million, down 4% in the quarter. R&D expenses increased 30% to $3.3 billion in the quarter primarily due to higher license and asset acquisition charges and an in-process research and development (IPR&D) impairment charge.
Read Contract Pharma's Top Companies Report on BMS.
